Supernus Pharmaceuticals, Inc. (SUPN:NASDAQ) closed at $40.50 on October 23, 2026, down 3.73% on the day. The stock trades 32.1% below its 52-week high of $59.68 and 7.9% above its 52-week low of $37.54. Over the past year, it lost 19.1%. Supernus Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, SUPN closed higher on 114 days (45%). Its best day was August 5, 2026 (+8.46%) and its worst was November 5, 2025 (-17.35%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 2 times.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Find more stocks like SUPN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.